Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $29.12 billion. The enterprise value is $35.75 billion.
| Market Cap | 29.12B |
| Enterprise Value | 35.75B |
Important Dates
The next confirmed earnings date is Wednesday, April 24, 2024, before market open.
| Earnings Date | Apr 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 145.36 million shares outstanding. The number of shares has decreased by -0.27% in one year.
| Shares Outstanding | 145.36M |
| Shares Change (YoY) | -0.27% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 93.01% |
| Float | 144.82M |
Valuation Ratios
The trailing PE ratio is 25.42 and the forward PE ratio is 12.90. Biogen's PEG ratio is 6.24.
| PE Ratio | 25.42 |
| Forward PE | 12.90 |
| PS Ratio | 3.00 |
| Forward PS | 3.05 |
| PB Ratio | 1.99 |
| P/FCF Ratio | 23.84 |
| PEG Ratio | 6.24 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.96, with an EV/FCF ratio of 28.93.
| EV / Earnings | 30.79 |
| EV / Sales | 3.64 |
| EV / EBITDA | 19.96 |
| EV / EBIT | 27.58 |
| EV / FCF | 28.93 |
Financial Position
The company has a current ratio of 2.00, with a Debt / Equity ratio of 0.50.
| Current Ratio | 2.00 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | 4.10 |
| Debt / FCF | 5.94 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 8.10% and return on invested capital (ROIC) is 5.25%.
| Return on Equity (ROE) | 8.10% |
| Return on Assets (ROA) | 4.40% |
| Return on Capital (ROIC) | 5.25% |
| Revenue Per Employee | $1.30M |
| Profits Per Employee | $153,382 |
| Employee Count | 7,570 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, Biogen has paid $135.30 million in taxes.
| Income Tax | 135.30M |
| Effective Tax Rate | 10.44% |
Stock Price Statistics
The stock price has decreased by -31.66% in the last 52 weeks. The beta is -0.01, so Biogen's price volatility has been lower than the market average.
| Beta (1Y) | -0.01 |
| 52-Week Price Change | -31.66% |
| 50-Day Moving Average | 213.40 |
| 200-Day Moving Average | 244.04 |
| Relative Strength Index (RSI) | 43.53 |
| Average Volume (30 Days) | 1,201,566 |
Short Selling Information
The latest short interest is 3.55 million, so 2.44% of the outstanding shares have been sold short.
| Short Interest | 3.55M |
| Short Previous Month | 2.66M |
| Short % of Shares Out | 2.44% |
| Short % of Float | 2.45% |
| Short Ratio (days to cover) | 2.66 |
Income Statement
In the last 12 months, Biogen had revenue of $9.84 billion and earned $1.16 billion in profits. Earnings per share was $7.97.
| Revenue | 9.84B |
| Gross Profit | 7.30B |
| Operating Income | 1.30B |
| Pretax Income | 1.30B |
| Net Income | 1.16B |
| EBITDA | 1.79B |
| EBIT | 1.30B |
| Earnings Per Share (EPS) | $7.97 |
Balance Sheet
The company has $1.05 billion in cash and $7.34 billion in debt, giving a net cash position of -$6.29 billion or -$43.26 per share.
| Cash & Cash Equivalents | 1.05B |
| Total Debt | 7.34B |
| Net Cash | -6.29B |
| Net Cash Per Share | -$43.26 |
| Equity / Book Value | 14.80B |
| Book Value Per Share | 101.81 |
| Working Capital | 3.43B |
Cash Flow
In the last 12 months, operating cash flow was $1.55 billion and capital expenditures -$311.40 million, giving a free cash flow of $1.24 billion.
| Operating Cash Flow | 1.55B |
| Capital Expenditures | -311.40M |
| Free Cash Flow | 1.24B |
| FCF Per Share | $8.54 |
Margins
Gross margin is 74.24%, with operating and profit margins of 13.18% and 11.81%.
| Gross Margin | 74.24% |
| Operating Margin | 13.18% |
| Pretax Margin | 13.18% |
| Profit Margin | 11.81% |
| EBITDA Margin | 18.21% |
| EBIT Margin | 13.18% |
| FCF Margin | 12.56% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.27% |
| Shareholder Yield | 0.27% |
| Earnings Yield | 3.94% |
| FCF Yield | 4.19% |
Analyst Forecast
The average price target for Biogen is $295.96, which is 47.70% higher than the current price. The consensus rating is "Buy".
| Price Target | $295.96 |
| Price Target Difference | 47.70% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (5Y) | 2.73% |
| EPS Growth Forecast (5Y) | 24.08% |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.07 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.07 |
| Piotroski F-Score | 5 |